Publications by authors named "Edward Spangenthal"
Background: Immune checkpoint inhibitors (ICI) have emerged as a front-line therapy for a variety of solid tumors. With the widespread use of these agents, immune-associated toxicities are increasingly being recognized, including fatal myocarditis. There are limited data on the outcomes and prognostic utility of biomarkers associated with ICI-associated myocarditis.
View Article and Find Full Text PDFArticle Synopsis
- An 84-year-old man had a serious health issue where he was diagnosed with colon cancer after experiencing blood in his stool.
- He had a history of heart problems and needed special treatments to help his heart before getting surgery for the cancer.
- After surgery, he recovered well and is healthy with no signs of the cancer coming back for over a year!
Article Synopsis
- The introduction of immune checkpoint inhibitors (ICIs) has transformed cancer treatment but often leads to various immune-related adverse events, particularly cardiac toxicity.
- Cardiovascular issues can range from mild symptoms like elevated troponin levels to severe conditions like myocarditis, which can be life-threatening, although it's rare.
- A case series from Roswell Park Comprehensive Cancer Center emphasizes the need for healthcare providers to quickly identify myocarditis and start immunosuppressive treatment to manage these complications effectively.
Anthracyclines constitute the backbone of intensive adult acute myeloid leukemia (AML) therapy. Cardiotoxicity is one of its most serious adverse effects, and its incidence increases with cumulative dose. Dexrazoxane is a cardioprotective agent used in conjunction with anthracycline therapy.
View Article and Find Full Text PDFArticle Synopsis
- The use of gonadotropin-releasing hormone (GnRH) agonists in advanced prostate cancer can trigger a testosterone surge, leading to disease flare, which is concerning for patients.
- A common preventive strategy is to start antiandrogen treatment before GnRH agonist therapy, but this may be unsafe for patients at high risk of organ damage.
- Instead, using newer treatments like GnRH antagonists and CYP17 enzyme inhibitors can quickly lower testosterone levels without the side effects associated with antiandrogens, as demonstrated in three emergency cases.
Cancer therapeutics is undergoing a revolution with the advent of new drugs that can selectively target molecules responsible for carcinogenesis and tumor growth. The type and mechanism of these targeting drugs vary. Some are small molecules that specifically target a binding site on a receptor or signal transduction molecule.
View Article and Find Full Text PDFBackground: Hypertension (HT) is a common complication of anti-angiogenic therapy. Its incidence, treatment and complications are undefined.
Patients And Methods: Retrospective review of patients treated with bevacizumab (BV) from 2003-5.